1 – 35 of 35
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Uncovering causal clues in the development of second primary cancers
(
- Contribution to journal › Letter
- 2023
-
Mark
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1) : final survival analysis of a randomised, controlled, phase 3 trial
(
- Contribution to journal › Article
-
Mark
Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI) : a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study
(
- Contribution to journal › Article
- 2021
-
Mark
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): : initial results from an international prospective study
(
- Contribution to journal › Article
-
Mark
Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study
(
- Contribution to journal › Article
- 2019
-
Mark
Master protocols in clinical trials : a universal Swiss Army knife?
(
- Contribution to journal › Scientific review
-
Mark
Tomosynthesis in breast screening : great expectations?
(
- Contribution to journal › Article
- 2018
-
Mark
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer : meta-analysis of individual patient data from ten randomised trials
- Contribution to journal › Article
- 2016
-
Mark
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
(
- Contribution to journal › Article
-
Mark
Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas
(
- Contribution to journal › Debate/Note/Editorial
- 2015
-
Mark
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
(
- Contribution to journal › Article
-
Mark
Endometrial cancer and oral contraceptives : an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies
(
- Contribution to journal › Article
-
Mark
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) : final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
(
- Contribution to journal › Article
-
Mark
Global cancer surgery: delivering safe, affordable, and timely cancer surgery
(
- Contribution to journal › Article
-
Mark
Towards "next-generation" prostate cancer screening.
(
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
Prevention and early detection of prostate cancer.
(
- Contribution to journal › Scientific review
-
Mark
Local treatments for metastases of renal cell carcinoma: a systematic review
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries
(
- Contribution to journal › Article
-
Mark
Air pollution and lung cancer in Europe - Authors' reply
(
- Contribution to journal › Letter
- 2012
-
Mark
Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies
(
- Contribution to journal › Article
-
Mark
Cancer incidence in patients with polyglutamine diseases: a population-based study in Sweden.
(
- Contribution to journal › Article
-
Mark
Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies
(
- Contribution to journal › Article
-
Mark
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study
(
- Contribution to journal › Article
-
Mark
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
(
- Contribution to journal › Article
- 2010
-
Mark
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
(
- Contribution to journal › Article
-
Mark
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
(
- Contribution to journal › Article
-
Mark
Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
(
- Contribution to journal › Article
- 2009
-
Mark
Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway
(
- Contribution to journal › Article
- 2008
-
Mark
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
(
- Contribution to journal › Article
- 2007
-
Mark
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
(
- Contribution to journal › Article
-
Mark
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
(
- Contribution to journal › Article
- 2006
-
Mark
Should donors be allowed to give broad consent to future biobank research?
(
- Contribution to journal › Article
-
Mark
Survival from rare cancer in adults: a population-based study
(
- Contribution to journal › Article
- 2005
-
Mark
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
(
- Contribution to journal › Article
- 2002
-
Mark
Genetic testing for melanoma
(
- Contribution to journal › Article